FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2028241711> ?p ?o ?g. }

• W2028241711 endingPage "100" @default.
• W2028241711 startingPage "94" @default.
• W2028241711 abstract "Dogs are the main reservoir host for zoonotic visceral leishmaniasis, a sand fly-borne disease caused by Leishmania infantum. In endemic areas, “susceptible” dogs suffer from a severe disease characterized by chronic polymorphic viscerocutaneous signs that manifest several months from the exposure, whereas “resistant” dogs can remain subclinically infected for years or lifelong. The protective immune response to Leishmania is cell-mediated; for visceralizing Leishmania species a mixed T helper (Th)1/Th2 response with a dominant Th1 profile is required for protection. The activation of the adaptive immune system in naturally resistant dogs is revealed by parasite-specific lymphoproliferation, delayed-type hypersensitivity, the production of interferon-γ and tumour necrosis factor-α cytokines, and enhanced macrophage leishmanicidal activity via nitric oxide. Hence, an effective canine Leishmania vaccine should induce strong and long-lasting Th1-dominated immunity to control both infection progression and the parasite transmissibility via the vector. Preclinical research in rodent models has evaluated the efficacy of several categories of Leishmania antigens including killed parasites, cell purified fractions, parasite protein components or subunits, single or multiple chimeric recombinant proteins, plasmid DNA and viral particles encoding parasite virulence factors. Promising antigen(s)/adjuvant combinations from each of the above categories have also been tested in dogs; they mostly resulted in limited or no protection in Phase I–II studies (designed to test vaccine safety, immunogenicity and laboratory-induced protection) in which vaccinated dogs were challenged by the artificial intravenous injection of high-load L. infantum promastigotes. The recombinant A2 antigen plus saponin conferred about 40% protection against infection by this challenge system and has been registered in Brazil as a canine vaccine (LeishTec®). An increasing number of efficacy studies have privileged the use of natural challenge consisting in the long-term exposure of vaccinated dogs in endemic settings (Phase III). A 2-year field model including regular assessments by a set of standard diagnostic markers useful for an accurate infection staging has been developed. Again, most of the vaccines tested by this system, which included several antigen categories and adjuvants, failed to protect against infection and disease. Only two vaccines, consisting of parasite purified fractions with saponin derivative adjuvants, showed to confer significant protection against disease and death under natural conditions, and have been registered as canine vaccines: FML-QuilA (Leishmune®) in Brazil, and LiESP/QA-21 (CaniLeish®) in Europe." @default.
• W2028241711 created "2016-06-24" @default.
• W2028241711 creator A5025839671 @default.
• W2028241711 date "2015-02-01" @default.
• W2028241711 modified "2023-09-25" @default.
• W2028241711 title "Canine Leishmania vaccines: Still a long way to go" @default.
• W2028241711 cites W1981395255 @default.
• W2028241711 cites W1987269179 @default.
• W2028241711 cites W1990289934 @default.
• W2028241711 cites W1991598090 @default.
• W2028241711 cites W1993596984 @default.
• W2028241711 cites W1996979641 @default.
• W2028241711 cites W2000052617 @default.
• W2028241711 cites W2001185068 @default.
• W2028241711 cites W2012813469 @default.
• W2028241711 cites W2014050422 @default.
• W2028241711 cites W2014452639 @default.
• W2028241711 cites W2016706918 @default.
• W2028241711 cites W2021712302 @default.
• W2028241711 cites W2022412760 @default.
• W2028241711 cites W2024813430 @default.
• W2028241711 cites W2026685638 @default.
• W2028241711 cites W2027969728 @default.
• W2028241711 cites W2032056858 @default.
• W2028241711 cites W2033785669 @default.
• W2028241711 cites W2035486819 @default.
• W2028241711 cites W2049295129 @default.
• W2028241711 cites W2050886892 @default.
• W2028241711 cites W2051703773 @default.
• W2028241711 cites W2063694051 @default.
• W2028241711 cites W2073465476 @default.
• W2028241711 cites W2078543128 @default.
• W2028241711 cites W2079048552 @default.
• W2028241711 cites W2080951592 @default.
• W2028241711 cites W2080975571 @default.
• W2028241711 cites W2084208767 @default.
• W2028241711 cites W2095331802 @default.
• W2028241711 cites W2095999453 @default.
• W2028241711 cites W2107915297 @default.
• W2028241711 cites W2125094009 @default.
• W2028241711 cites W2125345027 @default.
• W2028241711 cites W2126023291 @default.
• W2028241711 cites W2128166966 @default.
• W2028241711 cites W2131902485 @default.
• W2028241711 cites W2139390213 @default.
• W2028241711 cites W2139926426 @default.
• W2028241711 cites W2141677295 @default.
• W2028241711 cites W2141800850 @default.
• W2028241711 cites W2143184055 @default.
• W2028241711 cites W2144802819 @default.
• W2028241711 cites W2149000113 @default.
• W2028241711 cites W2162160321 @default.
• W2028241711 cites W2168724482 @default.
• W2028241711 cites W4211253687 @default.
• W2028241711 cites W4233424756 @default.
• W2028241711 doi "https://doi.org/10.1016/j.vetpar.2015.01.003" @default.
• W2028241711 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25620293" @default.
• W2028241711 hasPublicationYear "2015" @default.
• W2028241711 type Work @default.
• W2028241711 sameAs 2028241711 @default.
• W2028241711 citedByCount "90" @default.
• W2028241711 countsByYear W20282417112015 @default.
• W2028241711 countsByYear W20282417112016 @default.
• W2028241711 countsByYear W20282417112017 @default.
• W2028241711 countsByYear W20282417112018 @default.
• W2028241711 countsByYear W20282417112019 @default.
• W2028241711 countsByYear W20282417112020 @default.
• W2028241711 countsByYear W20282417112021 @default.
• W2028241711 countsByYear W20282417112022 @default.
• W2028241711 countsByYear W20282417112023 @default.
• W2028241711 crossrefType "journal-article" @default.
• W2028241711 hasAuthorship W2028241711A5025839671 @default.
• W2028241711 hasConcept C136764020 @default.
• W2028241711 hasConcept C147483822 @default.
• W2028241711 hasConcept C159047783 @default.
• W2028241711 hasConcept C167508917 @default.
• W2028241711 hasConcept C203014093 @default.
• W2028241711 hasConcept C22070199 @default.
• W2028241711 hasConcept C2776555147 @default.
• W2028241711 hasConcept C2777625542 @default.
• W2028241711 hasConcept C2777863537 @default.
• W2028241711 hasConcept C2778689377 @default.
• W2028241711 hasConcept C2779341262 @default.
• W2028241711 hasConcept C2780599195 @default.
• W2028241711 hasConcept C2780801004 @default.
• W2028241711 hasConcept C2780868878 @default.
• W2028241711 hasConcept C2781092759 @default.
• W2028241711 hasConcept C2781257258 @default.
• W2028241711 hasConcept C41008148 @default.
• W2028241711 hasConcept C71928629 @default.
• W2028241711 hasConcept C86803240 @default.
• W2028241711 hasConcept C8891405 @default.
• W2028241711 hasConceptScore W2028241711C136764020 @default.
• W2028241711 hasConceptScore W2028241711C147483822 @default.
• W2028241711 hasConceptScore W2028241711C159047783 @default.
• W2028241711 hasConceptScore W2028241711C167508917 @default.
• W2028241711 hasConceptScore W2028241711C203014093 @default.
• W2028241711 hasConceptScore W2028241711C22070199 @default.

• next